Very small size proteoliposomes derived from Neisseria meningitidis:: An effective adjuvant for generation of CTL responses to peptide and protein antigens

被引:34
作者
Mesa, C [1 ]
de León, J [1 ]
Fernández, LE [1 ]
机构
[1] Ctr Mol Immunol, Vaccines Dept, C Habanna 16040, Cuba
关键词
CTL; cross-priming; Neisseria meningitidis;
D O I
10.1016/j.vaccine.2005.08.111
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The development of potent adjuvants, conditioning innate and adaptative immunity, particularly CTL responses, has become currently a hot point in the rational design of vaccines for cancer immunotherapy. We have described a new approach, in which gangliosides are incorporated into vesicles from Neisseria meningitidis to form Very Small Size Proteoliposomes (VSSP). VSSP is a good alternative to the existing adjuvants for use in whole cells vaccines since it promotes 80% tumour rejection and growing delay in the CT26 and F3II tumour models respectively. Also VSSP induces activation of CTL responses to co-injected trimmed peptides and soluble proteins. This phenomena is facilitated by the cross-presentation of exogenous antigen and do not need cooperation of CD4 T cells for primary CD8 T cells expansion. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2692 / 2699
页数:8
相关论文
共 44 条
[21]   Sulforaphane: a naturally occurring mammary carcinoma mitotic inhibitor, which disrupts tubulin polymerization [J].
Jackson, SJT ;
Singletary, KW .
CARCINOGENESIS, 2004, 25 (02) :219-227
[22]  
JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P657
[23]   CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes [J].
Janssen, EM ;
Lemmens, EE ;
Wolfe, T ;
Christen, U ;
von Herrath, MG ;
Schoenberger, SP .
NATURE, 2003, 421 (6925) :852-856
[24]   OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway [J].
Jeannin, P ;
Renno, T ;
Goetsch, L ;
Miconnet, I ;
Aubry, JP ;
Delneste, Y ;
Herbault, N ;
Baussant, T ;
Magistrelli, G ;
Soulas, C ;
Romero, P ;
Cerottini, JC ;
Bonnefoy, JY .
NATURE IMMUNOLOGY, 2000, 1 (06) :502-509
[25]   CERAMIDE STRUCTURE PREDICTS TUMOR GANGLIOSIDE IMMUNOSUPPRESSIVE ACTIVITY [J].
LADISCH, S ;
LI, RX ;
OLSON, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (05) :1974-1978
[26]   GANGLIOSIDES SHED BY TUMOR-CELLS ENHANCE TUMOR-FORMATION IN MICE [J].
LADISCH, S ;
KITADA, S ;
HAYS, EF .
JOURNAL OF CLINICAL INVESTIGATION, 1987, 79 (06) :1879-1882
[27]  
Lienard Danielle, 2004, Cancer Immun, V4, P4
[28]  
Maurer T, 2002, EUR J IMMUNOL, V32, P2356, DOI 10.1002/1521-4141(200208)32:8<2356::AID-IMMU2356>3.0.CO
[29]  
2-Z
[30]   Challenges facing adjuvants for cancer immunotherapy [J].
Mesa, C ;
Fernández, LE .
IMMUNOLOGY AND CELL BIOLOGY, 2004, 82 (06) :644-650